SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:763ab9cf-ba15-4ea7-833e-7ba4da24ffc0"
 

Search: onr:"swepub:oai:lup.lub.lu.se:763ab9cf-ba15-4ea7-833e-7ba4da24ffc0" > Monitoring of long-...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease

Hindorf, Ulf (author)
Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
Lyrenas, E (author)
Nilsson, Åke (author)
Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
show more...
Schmiegelow, K (author)
show less...
 (creator_code:org_t)
2009-07-08
2004
English.
In: Scandinavian Journal of Gastroenterology. - : Informa UK Limited. - 1502-7708 .- 0036-5521. ; 39:11, s. 1105-1112
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: The immunosuppressive effects of thiopurine drugs are mainly mediated through their intracellular metabolism into active 6-thioguanine nucleotide (6-TGN) metabolites, which are incorporated into DNA. Erythrocyte 6-TGN (E-6TGN) levels have been proposed as an instrument for monitoring treatment. The aim of the study was to use erythrocyte E-6TGN, methylated mercaptopurine (MeMP) metabolites, and thiopurine methyltransferase (TPMT) measurements in a clinical setting to determine the clinical outcome in relation to thiopurine metabolism. Methods: Fifty-five adult patients with inflammatory bowel disease were included in a prospective study and followed for 6 months. Metabolite levels were measured and correlated to outcome and AZA/6-MP dose. Results: The E-6TGN level was significantly related to the TPMT genotype ( P = 0.008). Patients in disease remission had higher E-6TGN levels than patients with disease activity both at baseline ( P < 0.05) and after 6 months ( P = 0.02). Active disease was more frequent among subjects with E-6TGN &LE; 125 nmol/mmol Hb at baseline ( P = 0.04), but not at 6 months. AZA/6-MP drug dose was positively correlated to E-MeMP levels (r(s) = 0.48; P < 0.001) and E-MeMP/E-6TGN ratio (r(s) = 0.41; P = 0.002). Dose changes were positively correlated with the changes in E-MeMP levels ( P = 0.01) and E-MeMP/E-6TGN ratio (P = 0.03). Conclusions: E-6TGN level was the only factor in this study related to disease activity, while there was no relationship between AZA/6-MP dose and E-6TGN levels. This finding illustrates the clinical usefulness of E-6TGN monitoring in the evaluation of treatment intensity.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Keyword

immunosuppressive agents
inflammatory bowel diseases
pharmacology
drug monitoring

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Hindorf, Ulf
Lyrenas, E
Nilsson, Åke
Schmiegelow, K
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Gastroenterology ...
Articles in the publication
Scandinavian Jou ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view